Calixa Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of a novel cephalosporin to address the expanding problem of multi-drug resistant organisms. Treatment of infections caused by resistant gram-negative bacteria, especially Pseudomonas aeruginosa, is recognized as an unmet medical need by the infectious diseases community.
Calixaâ€™s lead product, CXA-101, is an IV formulation of a novel cephalosporin that has excellent potency especially against multi-drug resistant Pseudomonas aeruginosa, which differentiates it from other cephalosporins. No similar drug is known to be in development. Calixa plans to combine this product with a Î²-lactamase inhibitor; the combination product (CXA-201) has the potential to become the first-line therapeutic choice for hospitalized patients suffering from serious infection caused by gram-negative organisms.
Current Team (2)Update
|Apr 12, 2016||PRNewswire UK All - Antibacterial Drugs: World Industry and Market Prospects 2016-2026|
|Jun 8, 2015||PRNewswire UK All - Antibacterial Drugs: World Industry and Market Prospects 2015-2025|
|Dec 8, 2014||Xconomy - Independent No More: Cubist Sold to Merck for $9.5B|
|Dec 16, 2013||Xconomy - Cubist Shares Climb As Antibiotic Scores in Phase 3 Again|
|Dec 6, 2013||Xconomy - East Coast Biotech Roundup: Juno, Editas, Celgene, & More|
|Nov 25, 2013||Xconomy - Cubist’s Calixa Buyout Bears Fruit as Antibiotic Hits First Phase 3 Mark|
|Feb 25, 2013||Xconomy - Cubist Grabs Option to Acquire Adynxx, Getting Drug for Pain|
|Aug 7, 2012||Xconomy - Domain-Backed Adynxx Enters the Wide Open World of Pain Drug R&D|
1840 Gateway Drive
San Mateo, California 94404